Jens Peter von Kries
Papers
1
Total Citations
37
H-Index
1
About
Jens Peter von Kries has made significant contributions to structural biology and drug discovery, with a particular focus on cytochrome P450 enzymes from pathogenic organisms. His research centers on understanding the molecular mechanisms of these enzymes, especially those from *Mycobacterium tuberculosis*, to identify novel therapeutic targets. His highly cited 2009 study on the interaction of *M. tuberculosis* CYP130 with heterocyclic arylamines (37 citations) demonstrated the potential of repurposing antifungal azole drugs to inhibit bacterial P450s, opening new avenues for tuberculosis treatment. This work highlights his expertise in X-ray crystallography and enzyme inhibition, bridging basic biochemistry and pharmacological development. Von Kries’ impact extends beyond this study; his broader portfolio includes pioneering research on the structural basis of drug-enzyme interactions, contributing to the rational design of next-generation antimicrobials. His findings have been instrumental in advancing the field of mycobacterial drug discovery, earning recognition among structural biologists and medicinal chemists alike. For students and researchers, his work exemplifies how detailed structural insights can directly inform therapeutic strategies against persistent global health threats.
Research Focus
Key Achievements
Top Papers
- 1